CA2406685C - Oxadiazole derivatives having anticancer effects - Google Patents

Oxadiazole derivatives having anticancer effects Download PDF

Info

Publication number
CA2406685C
CA2406685C CA002406685A CA2406685A CA2406685C CA 2406685 C CA2406685 C CA 2406685C CA 002406685 A CA002406685 A CA 002406685A CA 2406685 A CA2406685 A CA 2406685A CA 2406685 C CA2406685 C CA 2406685C
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
derivative
dmso
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002406685A
Other languages
English (en)
French (fr)
Other versions
CA2406685A1 (en
Inventor
Takayuki Yoshioka
Ryuji Maekawa
Fumihiko Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of CA2406685A1 publication Critical patent/CA2406685A1/en
Application granted granted Critical
Publication of CA2406685C publication Critical patent/CA2406685C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA002406685A 2000-04-21 2001-04-16 Oxadiazole derivatives having anticancer effects Expired - Fee Related CA2406685C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000120234 2000-04-21
JP2000-120234 2000-04-21
PCT/JP2001/003214 WO2001083463A1 (en) 2000-04-21 2001-04-16 Oxadiazole derivatives having anticancer effects

Publications (2)

Publication Number Publication Date
CA2406685A1 CA2406685A1 (en) 2002-10-17
CA2406685C true CA2406685C (en) 2006-10-31

Family

ID=18631080

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002406685A Expired - Fee Related CA2406685C (en) 2000-04-21 2001-04-16 Oxadiazole derivatives having anticancer effects

Country Status (16)

Country Link
US (2) US6720343B2 (enExample)
EP (1) EP1277744A4 (enExample)
JP (1) JP3974781B2 (enExample)
KR (1) KR100542780B1 (enExample)
CN (1) CN1199956C (enExample)
AU (2) AU4691601A (enExample)
BR (1) BR0110211A (enExample)
CA (1) CA2406685C (enExample)
HU (1) HUP0300619A3 (enExample)
MX (1) MXPA02010325A (enExample)
NO (1) NO324868B1 (enExample)
PL (1) PL203161B1 (enExample)
RU (1) RU2275371C2 (enExample)
TW (1) TWI294877B (enExample)
WO (1) WO2001083463A1 (enExample)
ZA (1) ZA200208307B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
WO2005012268A1 (ja) 2003-07-30 2005-02-10 Shionogi & Co., Ltd. イソオキサゾール環を有するスルホンアミド誘導体
CN101043887A (zh) * 2004-10-22 2007-09-26 默克公司 用作s1p受体激动剂的2－(芳基)氮杂环甲基羧酸酯、磺酸酯、膦酸酯、次膦酸酯和杂环化合物
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
GB0601744D0 (en) * 2006-01-27 2006-03-08 Novartis Ag Organic compounds
EP2258700A1 (en) * 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
KR100783585B1 (ko) 2006-08-22 2007-12-07 한국생명공학연구원 스탯의 활성을 저해하는 옥사다이아졸 우레아 화합물을 유효성분으로 함유하는 암의 예방 또는 치료제
JP5718053B2 (ja) 2007-08-27 2015-05-13 ヘリコン・セラピューティクス・インコーポレーテッド 治療用イソオキサゾール化合物
ES2403209T3 (es) * 2007-12-10 2013-05-16 Actelion Pharmaceuticals Ltd. Derivados de tiofeno novedosos como agonistas de S1P1/EDG1
UY32858A (es) 2009-08-31 2011-03-31 Abbott Healthcare Products Bv Derivados de (tio)morfolina como moduladores de sip
RU2415845C1 (ru) * 2009-10-14 2011-04-10 Государственное образовательное учреждение высшего профессионального образования "Астраханский государственный университет" (АГУ) Сульфонные производные 2-нитро-2-(3-арил-1,2,4-оксадиазол-5-ил)этана, обладающие противолепрозной и противотуберкулезной активностью
TWI543984B (zh) 2010-07-09 2016-08-01 艾伯維公司 作為s1p調節劑的螺-哌啶衍生物
TWI522361B (zh) 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
CN103450167A (zh) * 2012-05-28 2013-12-18 南京大学 一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物及其制备方法与用途
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
BR112022008113A2 (pt) 2019-10-31 2022-07-19 Escape Bio Inc Formas sólidas de um modulador de receptor s1p
CN113264899B (zh) * 2021-04-09 2022-06-14 台州学院 一种1，3，5-噁二嗪类化合物及其制备和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69836877D1 (de) * 1997-07-22 2007-02-22 Shionogi & Co Verwendung von Matrix- Metalloproteinase Inhibitoren zur Behandlung oder Vorbeugung von Glomerulopathie
WO2000015213A1 (en) 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Remedal or preventive agent for congestive heart failure

Also Published As

Publication number Publication date
KR20030019357A (ko) 2003-03-06
EP1277744A1 (en) 2003-01-22
CA2406685A1 (en) 2002-10-17
HUP0300619A3 (en) 2006-02-28
NO20025035L (no) 2002-12-19
RU2275371C2 (ru) 2006-04-27
AU2001246916B2 (en) 2004-10-07
CN1436179A (zh) 2003-08-13
US6720343B2 (en) 2004-04-13
JP3974781B2 (ja) 2007-09-12
US20040122066A1 (en) 2004-06-24
NO20025035D0 (no) 2002-10-18
EP1277744A4 (en) 2007-07-11
PL359415A1 (en) 2004-08-23
MXPA02010325A (es) 2003-04-25
ZA200208307B (en) 2003-10-15
CN1199956C (zh) 2005-05-04
WO2001083463A1 (en) 2001-11-08
AU4691601A (en) 2001-11-12
NO324868B1 (no) 2007-12-17
TWI294877B (enExample) 2008-03-21
PL203161B1 (pl) 2009-08-31
KR100542780B1 (ko) 2006-01-11
US20030203940A1 (en) 2003-10-30
HUP0300619A2 (hu) 2003-07-28
BR0110211A (pt) 2003-06-03

Similar Documents

Publication Publication Date Title
CA2406685C (en) Oxadiazole derivatives having anticancer effects
US6897237B2 (en) MMP-12 inhibitors
CN101605777A (zh) 作为醛固酮合酶抑制剂的咪唑类化合物
US6495578B1 (en) Sulfonamide derivatives having oxadiazole rings
JPWO2001083463A1 (ja) 抗癌作用を有するオキサジアゾール誘導体
US6949566B2 (en) Thiazole and oxazole derivatives
EP1491190A1 (en) Decomposition inhibitor for extracellular matrix of cartilage
JP4219810B2 (ja) Ｍｍｐ阻害作用を有するスルホンアミド誘導体
EP1491520A1 (en) Process for production of bisphenol a
US7825146B2 (en) Sulfonamide derivative having isoxazole ring
JPWO2000058304A1 (ja) 複素環状スルホンアミド誘導体
JPWO2000058280A1 (ja) 炭素環状スルホンアミド誘導体
JPWO2000058278A1 (ja) ベータアミノ酸誘導体
JPWO2001083461A1 (ja) チアゾールおよびオキサゾール誘導体
JPWO2006028038A1 (ja) Ｍｍｐ−１３を選択的に阻害するスルホンアミド誘導体
JPWO2000063194A1 (ja) オキサジアゾール環を有するスルホンアミド誘導体
JPWO2001083431A1 (ja) Ｍｍｐ−１２阻害剤
JPWO2001083464A1 (ja) 糸球体障害治療または予防作用を有するオキサジアゾール誘導体
MXPA99001831A (en) Novel peptide derivatives having thiazolyl-alanine residue

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130416

MKLA Lapsed

Effective date: 20130416